HANSOH PHARMA (03692) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Here's Why We Think Hansoh Pharmaceutical Group (HKG:3692) Might Deserve Your Attention Today
Simply Wall St19:39 ET
Hansoh Pharma (03692): Four innovative drugs renewed to be included in the 2024 national medical insurance catalog
Hansoh Pharma (03692) announced that the following four innovative drugs have been renewed for inclusion in china's National Medical Insurance Administration and Human Resources...
Zhitong FinanceNov 28 07:44 ET
Hong Kong Stock Announcement for Investment | sdhs new energy (01250) plans to receive a cash offer from sdhg (00412) at a premium of approximately 7.23%.
sdhs new energy (01250) intends to receive a cash offer from sdhg (00412) at a premium of about 7.23%; stanchart (02888) intends to first time exit minority business to increase investment in wealthy customer business.
Zhitong FinanceNov 27 10:01 ET
Hansoh Pharma (03692): The fifth listing license application for Amivor (Amitinib mesylate tablets) has been accepted by the National Medical Products Administration.
Hansoh Pharma (03692) announced that the group's innovative drug, Ameil (Amebix sulfate Ametinib tablet), the fifth...
Zhitong FinanceNov 27 05:33 ET
Express News | Hansoh Pharmaceutical - 5TH New Drug Application of Ameile (Aumolertinib Mesilate Tablets) Accepted by Nmpa China
ReutersNov 27 05:32 ET
National medical insurance drug list unveiling soon! Keji Pharmaceutical's stock surged over 9%, leading the way in Hong Kong pharmaceutical stocks.
1. What is the importance of centralized procurement of pharmaceutical companies by medical insurance? 2. Which areas of products are expected to be included in the 2024 National Medical Insurance Drug Catalog?
cls.cnNov 26 21:39 ET

Comments

Bull X Bear

Oct 3 02:14

What would you buy in your Hong Kong portfolio?

Banks: $ABC (01288.HK)$ $BANK OF CHINA (03988.HK)$
Securities & Brokerage: $HTSC (06886.HK)$ $CMSC (06099.HK)$
Gaming Software: $NTES-S (09999.HK)$ $XD INC (02400.HK)$ $NETDRAGON (00777.HK)$
Digital Solutions: $TENCENT (00700.HK)$ $TRAVELSKY TECH (00696.HK)$ $CHINASOFT INT'L (00354.HK)$
Online Retailer: $BABA-W (09988.HK)$ $MEITUAN-W (03690.HK)$ $JD-SW (09618.HK)$
Insurer: $PING AN (02318.HK)$ $AIA (01299.HK)$ $CHINA LIFE (02628.HK)$
Telecommunication: $CHINA MOBILE (00941.HK)$ $CHINA TELECOM (00728.HK)$
...

Officials say the real estate market is bottoming out. What’s your view on China's property market?

15

7

Trader’s Edge

Sep 25 06:05

Columns Chinese Market Blitzkrieg: Is it any different this time?

Background
Chinese indices have been ripping higher the past 2 days. To put things in perspective, this is only the 2nd time in 2024 (and since Jan 2023) where we see the onshore indices post a bigger rally than the HSI.
1st Time (February 2024):CSI 300 was up by+10% while the HSI was up by only +7.7%
2nd Time (September 2024):CSI 300 up by+6.3% while the HSI was up by only +4.9%
So... what led to this sudden outperformance?
On 24th Septem...

+2

Officials say the real estate market is bottoming out. What’s your view on China's property market?

42

4

Trader’s Edge

Sep 8 21:56

Columns Stocks we're watching this week - KMB, MET and more

Stocks to Watch
Kimberly-Clark Corporation (KMB US) $Kimberly-Clark (KMB.US)$
Daily Chart -[BULLISH ↗ **]KMB is holding above mid-term ascending trendline support and hasbeen making a series of higher highs and higher lows. As long as price is holding above 142 support, a further push higher towards 155.70 resistance is expected. Technical indicators are advocating for a bullish scenario.
Alternatively: A daily candlestick closingbelow 142 suppor...

+3

20

Moomoo AI

Mar 4 16:46

Hansoh Pharmaceutical Group's high P/E ratio may be due to expected earnings recovery. However, with lower than market growth forecast, the high P/E ratio and positive investor sentiment may not be sustainable. Current trading prices may not be reasonable without significant improvement.

Optimistic Investors Push Hansoh Pharmaceutical Group Company Limited (HKG:3692) Shares Up 28% But Growth Is Lacking

1

Moomoo AI

Feb 11 22:53

Hansoh Pharmaceutical Group's strong financials and moderate growth over the past five years, along with its high rate of profit reinvestment, could potentially boost its stock value in the long-term. Analysts anticipate future earnings momentum.

Hansoh Pharmaceutical Group Company Limited (HKG:3692) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?

03692 HANSOH PHARMA

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target